The Latest Breaking News from Moderna

Claims that artificial intelligence will change the way drugs are made are almost certainly overblown. Here’s why

The application for children ages 6 months to under 6 years is expected to be completed later this year.

Someone with a lot of money to spend has taken a bearish stance on Moderna (NASDAQ:MRNA). And retail traders should know. We noticed this today when the big position showed up on publicly available options history that we track here at Benzinga.

A whale with a lot of money to spend has taken a noticeably bearish stance on Moderna. Looking at options history for Moderna (NASDAQ:MRNA) we detected 35 strange trades.

People in Europe should take whatever COVID-19 booster is available to them in the coming months, Emer Cooke, Executive Director of the European Medicines Agency (EMA), said in a Reuters Next Newsmaker interview ahead of an expected autumn rise in infections.

Reuters

The omicron-specific booster vaccine hit the market — some wonder if it's worth getting

Last month, the FDA authorized omicron-specific vaccines, accompanied by breathless science-by-press release and a media blitz. Just days after the FDA’s move, the Centers for Disease Control and Prevention followed, recommending updated boosters for anyone age 12 and up who had received at least two doses of the original COVID-19…

SINGAPORE: Singapore on Wednesday granted interim authorisation for a bivalent Covid-19 booster vaccine made by Moderna, the government said in a statement.